Journal: Blood advances
This Advances in Hematology viewpoint reviews how immunotherapy is reshaping management of B‑cell precursor acute lymphoblastic leukemia (BCP‑ALL), with emphasis on adults and newly diagnosed disease.
Key points:
- Scope and focus
- • Describes current immunotherapeutic strategies in BCP‑ALL: monoclonal antibodies, bispecific T‑cell engagers, and CAR T‑cell therapy.
- • Centers on mechanisms of action, optimal timing of use (frontline vs relapsed/refractory), patient selection, and resistance.
- Major modalities
- • Monoclonal antibodies: Target lineage‑specific antigens on leukemic blasts; activity enhanced when combined with chemotherapy.
- • Bispecific T‑cell engagers: Redirect endogenous T cells to leukemic cells; particularly relevant in relapsed/refractory settings and as a bridge to transplant or CAR T therapy.
- • CAR T‑cell therapy: Genetically engineered autologous T cells targeting leukemia-associated antigens; can induce deep remissions in heavily pretreated patients.
- Clinical evidence
- • Summarizes pivotal trials that established each modality in BCP‑ALL, focusing on improvements in remission rates and survival in relapsed/refractory disease.
- • Highlights emerging data supporting integration of immunotherapy earlier in the treatment course, including in newly diagnosed adult patients.
- Resistance and limitations
- • Outlines mechanisms of resistance such as antigen loss/modulation and T‑cell dysfunction.
- • Notes challenges around durability of response, toxicity, and access.
- Future directions and perspective
- • Discusses rational sequencing and combination of immunotherapies with chemotherapy and/or transplant.
- • Proposes strategies to better exploit immunotherapy in frontline adult BCP‑ALL, aiming to improve cure rates while potentially reducing conventional chemotherapy intensity.